Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background & Aims: Nonalcoholic fatty liver disease (NAFLD) has been associated with sarcopenia. However, mortality in the setting of NAFLD‐related sarcopenia remains undefined. We aim to determine the all‐cause and cause‐specific mortality from sarcopenia among adults with NAFLD in the USA. Methods: 11 065 individuals in the Third National Health and Nutrition Examination Survey were studied and linked mortality through 2015 was analysed. NAFLD was diagnosed based on presence of ultrasonographic hepatic steatosis without other known liver diseases. Sarcopenia was defined as skeletal muscle index determined by bioelectrical impedance analysis. The Cox proportional hazard model was used to assess all‐cause mortality and cause‐specific mortality, and hazard ratio (HR) adjusted for known risk factors. Results: During a median follow‐up of 23 years or more, sarcopenia was associated with increased all‐cause mortality (HR 1.27, 95% confidence interval [CI] 1.11‐1.44). Only in individuals with NAFLD, sarcopenia was associated with a higher risk for all‐cause mortality, while this association was absent in those without NAFLD. Individuals with both sarcopenia and NAFLD had a higher risk for all‐cause mortality (HR 1.28 95% CI 1.06‐1.55) compared with those without sarcopenia and NAFLD. Furthermore, sarcopenia was associated with a higher risk for cancer‐ and diabetes‐related mortality among those with NAFLD. This association was not noted in those without NAFLD. Conclusion: In this nationally representative sample of US adults, sarcopenia was associated with a higher risk for all‐cause, cancer‐ and diabetes‐related mortality in individuals with NAFLD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., Harrison, S. A., Brunt, E. M., & Sanyal, A. J. (2018) · Hepatology · doi:10.1002/hep.29367 · Cited by 7,239
EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
(2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.11.004 · Cited by 4,836
Janssen, I., Heymsfield, S. B., & Ross, R. (2002) · Journal of the American Geriatrics Society · doi:10.1046/j.1532-5415.2002.50216.x · Cited by 3,139
Estimation of skeletal muscle mass by bioelectrical impedance analysis
Janssen, I., Heymsfield, S. B., Baumgartner, R. N., & Ross, R. (2000) · Journal of Applied Physiology · doi:10.1152/jappl.2000.89.2.465 · Cited by 1,482
Kim, D., Kim, R. W., Kim, H. J., & Therneau, T. M. (2013) · Hepatology · doi:10.1002/hep.26156 · Cited by 772
Self-citationPrevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes
Kim, T. N., Park, M. S., Yang, S. J., Yoo, H. J., Kang, H. J., Song, W., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2310 · Cited by 585
Hallsworth, K., Fattakhova, G., Hollingsworth, K. G., Thoma, C., Moore, S., Taylor, R., Day, C. P., & Trenell, M. I. (2011) · Gut · doi:10.1136/gut.2011.242073 · Cited by 529
Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis
Koo, B. K., Kim, D., Joo, S. K., Kim, J. H., Chang, M. S., Kim, B. G., Lee, K. L., & Kim, W. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.08.019 · Cited by 440
Self-citationHong, H. C., Hwang, S. Y., Choi, H. Y., Yoo, H. J., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., Choi, D. S., & Choi, K. M. (2014) · Hepatology · doi:10.1002/hep.26716 · Cited by 385
Bacchi, E., Negri, C., Targher, G., Faccioli, N., Lanza, M., Zoppini, G., Zanolin, E., Schena, F., Bonora, E., & Moghetti, P. (2013) · Hepatology · doi:10.1002/hep.26393 · Cited by 350
Cited by
Metabolic dysfunction-associated steatotic liver disease (MASLD): a state-of-the-art review
Chan, W.-K., Chuah, K.-H., Rajaram, R. B., Lim, L.-L., Ratnasingam, J., & Vethakkan, S. R. (2023) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes23052 · Cited by 776
Henry, A., Paik, J. M., Austin, P., Eberly, K. E., Golabi, P., Younossi, I., Henry, L., Gerber, L., & Younossi, Z. M. (2023) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17308 · Cited by 61
Osteosarcopenia in NAFLD/MAFLD: an underappreciated clinical problem in chronic liver disease
Musio, A., Perazza, F., Leoni, L., Stefanini, B., Dajti, E., Menozzi, R., Petroni, M. L., Colecchia, A., & Ravaioli, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24087517 · Cited by 26
“Furthermore, sarcopenia in NAFLD patients has been associated with adverse clinical outcomes, including a higher 10-year major osteoporotic and hip fracture probability [52], increased risk of albuminuria [53] and atherosclerotic cardiovascular disease (ASCVD) [46,54,55], and increased risk of all-cause [25,56–59], ca…”
Background
Metadata
- Authors
- Kim, D., Wijarnpreecha, K., Sandhu, K. K., Cholankeril, G., & Ahmed, A.
- Venue
- Liver International
- Publisher
- Wiley
- Published
- 2021-03-11
- Volume
- 41
- Issue
- 8
- Pages
- 1832-1840
- ISSN
- 0106-9543 (ISSN-L)
- 1478-3223
- 1478-3231
- OpenAlex
- W3134887736
- Cited by
- 66
- References
- 13
- FWCI
- 6.53
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States. https://app.cochat.ai/papers/10.1111/liv.14852
- The paper
- Kim, D., Wijarnpreecha, K., Sandhu, K. K., Cholankeril, G., & Ahmed, A. (2021). Sarcopenia in nonalcoholic fatty liver disease and all‐cause and cause‐specific mortality in the United States. Liver International. https://doi.org/10.1111/liv.14852
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.